Cargando…

Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers

Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progress...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Kevin C., Roy, Sushmita Mimi, Becker, Christopher H., Hafler, David A., Kantor, Aaron B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054/
https://www.ncbi.nlm.nih.gov/pubmed/17124343
http://dx.doi.org/10.1155/2006/670439
_version_ 1782294214727434240
author O’Connor, Kevin C.
Roy, Sushmita Mimi
Becker, Christopher H.
Hafler, David A.
Kantor, Aaron B.
author_facet O’Connor, Kevin C.
Roy, Sushmita Mimi
Becker, Christopher H.
Hafler, David A.
Kantor, Aaron B.
author_sort O’Connor, Kevin C.
collection PubMed
description Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation.
format Online
Article
Text
id pubmed-3851054
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38510542013-12-18 Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers O’Connor, Kevin C. Roy, Sushmita Mimi Becker, Christopher H. Hafler, David A. Kantor, Aaron B. Dis Markers Other Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation. IOS Press 2006 2006-11-15 /pmc/articles/PMC3851054/ /pubmed/17124343 http://dx.doi.org/10.1155/2006/670439 Text en Copyright © 2006 Hindawi Publishing Corporation.
spellingShingle Other
O’Connor, Kevin C.
Roy, Sushmita Mimi
Becker, Christopher H.
Hafler, David A.
Kantor, Aaron B.
Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title_full Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title_fullStr Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title_full_unstemmed Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title_short Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
title_sort comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054/
https://www.ncbi.nlm.nih.gov/pubmed/17124343
http://dx.doi.org/10.1155/2006/670439
work_keys_str_mv AT oconnorkevinc comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers
AT roysushmitamimi comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers
AT beckerchristopherh comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers
AT haflerdavida comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers
AT kantoraaronb comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers